Global Bariatric Surgery Devices Market - 2022-2029

Global Bariatric Surgery Devices Market - 2022-2029

Market Overview

Bariatric Surgery Devices Market is expected to grow at a CAGR 5% during the forecast period (2022-2029).

Bariatric surgical procedures reduce weight by restricting the amount of food the stomach can hold, causing malabsorption of nutrients, or combining gastric restriction and malabsorption. Most weight-loss surgeries are performed using minimally invasive techniques. People can reduce their weight by 15 to 30 percent of their starting weight on average, depending on the type of surgery they opt. Surgeons use various devices during the procedure depending upon the type of surgery.

Market Dynamics

Emerging technology in robotic bariatric surgery is expected to drive market growth.

Morbid obesity is becoming more common in the United States and worldwide. In the United States, 65% of adults are classified as overweight (BMI >25) or obese (BMI >30). The majority of the rise is in the obese population, with more than 6% being severely obese (BMI greater than 40). Surgical technology advancements have enabled procedures to be conducted safely using less invasive approaches. They have improved the outcomes of bariatric surgery to the point where it is now superior to intensive medical therapy in terms of both weight reduction and overall long-term mortality, even when perioperative morbidity and mortality are considered. For instance, sleeve gastrectomy and Roux-en-Y gastric bypass are both laparoscopic and, more recently, robotic procedures. Studies comparing laparoscopic and robotic operations reveal comparable morbidity, mortality, and weight loss results. However, technological complications may develop when operating on individuals with BMIs greater than 50. These patients face anatomical problems, such as strong abdominal walls (especially in female patients), which may necessitate excessive torque to the laparoscopic trocars and tools, resulting in tissue trauma, less precise motions, and surgeon fatigue. In addition, achieving pneumoperitoneum in superobese patients is more challenging, necessitating higher insufflation pressures and narrower intra-abdominal working space, making delicate dissection difficult. Therefore, the wristed, 3-dimensional movements and high-definition magnified views achieved by the DaVinci robotic instruments and cameras allow surgeons to use this platform to overcome these technical challenges. Furthermore, the robotic arms have precise movements with enough mechanical power to minimize the torque required to maneuver surgical instruments and minimize the risk of trauma to the abdominal wall, resulting in less postoperative pain and a faster recovery. Thus, the robotic platform has now proven to be as safe and effective as the traditional laparoscopic procedure, which has driven the practice and safety of bariatric surgery.

Restraint:

The costly surgical procedures, post-operative consequences, and lack of skilled professionals hamper the global adoption of bariatric surgery devices over the forecast period. For instance, blood clots, infection, bleeding, constipation, and gallstones, among other side effects of bariatric surgery, are major issues preventing individuals from undergoing surgery for weight loss. Furthermore, post-operative hazards are very common in patients, including acid reflux, protein or calorie deficiency, gallstones, constipation, stomach obstruction, and so on. Several studies also reveal greater mental health hazards. It is believed that more than 20% of patients considering and following bariatric surgery have behavioral health issues such as anxiety, binge-eating disorder, and depression, among others.

Industry Analysis

The bariatric surgery Devices market provides in-depth analysis of the market based on various industry factors such as porter five forces, unmet needs, pricing analysis, supply chain analysis, regulatory analysis etc.

COVID-19 Impact Analysis

The ongoing COVID-19 pandemic has strongly affected the delivery of surgical care worldwide. COVID-19, influenced by lockdown and work-from-home adoption, will increase sedentary lifestyles, resulting in a more obese population and expanding the potential for the bariatric surgical devices industry. Moreover, elective procedures have been postponed to reallocate resources to COVID-19 patients. Preoperative upper gastrointestinal tract endoscopies, outpatient clinic appointments, and bariatric procedures were all postponed by the majority of respondents. Instead of meeting patients in outpatient clinics, most surgeons use video conferencing for follow-up sessions. Although laparoscopy remained the recommended treatment for surgical emergencies, there was a tendency toward conservative treatment of acute appendicitis and acute cholecystitis. Because rapid preoperative COVID-19 testing was not commonly available, routine screening of emergency bariatric cases was not frequently performed. The participants used a wide range of safeguards and personal safety equipment.

Additionally, the pandemic interrupted the supply chain for bariatric surgery devices. Thus, the COVID-19 pandemic has affected the market. However, the situation is expected to improve gradually in the forecast period.

Segment Analysis/B>

Sleeve Gastrectomy segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

Sleeve gastrectomy is a safe and effective bariatric surgery to help obese people lose weight. Sleeve gastrectomy may be performed as a single procedure or as the initial stage before a gastric bypass. Sleeve gastrectomy includes an average weight loss of more than 50% of excess body weight, preserved stomach function because the nerves of the stomach and the outlet valve are not changed, and a lower risk of developing vitamin and mineral deficiencies because the food you eat follows the normal digestive path. Moreover, the surgeon only uses the laparoscopic approach for sleeve gastrectomy surgery due to the many benefits of laparoscopic surgery, which include less pain and a lower need for pain medication, a lower risk of wound infection, a quicker recovery and return to daily activities, several small incisions rather than a large one, and shorter hospital stays. Additionally, in June 2021, Standard Bariatrics, Inc. launched Titan SGS. This device aids surgeons in sleeve gastrectomy, with the industry's longest continuous staple cutline of 23 centimeters, and is the most frequently used bariatric surgery for obesity. Therefore, it has increased the demand for sleeve gastrectomy procedures. Thus, from the above statements, the market segment accounted for the largest market share in the forecast period.

Geographical Analysis

North American region holds the largest market share of the global bariatric surgery devices market.

In 2021, the North American region accounted for the largest market share. The increasing prevalence of obesity, technological advancements in bariatric surgery devices, and rising awareness regarding obesity in the region are the factors driving the market in the forecast period. For instance, many Americans have put on a lot of weight since the COVID-19 crisis began, probably due to a rise in sedentary behavior, stress, and issues like job and income loss that make healthy eating challenging. Moreover, the obesity rate in the general population is expected to reach around 42% by 2020, with the obesity rate increasing year after year, leading to an increase in the incidence of chronic diseases in adults. Obesity can cause serious health concerns and a considerable increase in mortality and morbidity. The region also has a substantially higher acceptance rate for weight loss surgery procedures, which helps the industry drive.

Additionally, Grantmakers In Health (GIH), an educational nonprofit dedicated to assisting foundations and corporate giving programs in improving the health of all people by strengthening the grantmaking community's knowledge, skills, and effectiveness, has been working to reduce childhood obesity rates for over a decade. GIH has recently concentrated on policy formulation and boosting access to nutritious food and physical activity. Furthermore, GIH uses a variety of platforms to bring together grantmakers and health experts and provide instructional materials, including meetings, forums, webinars, and publications. Recent GIH programming on childhood obesity has focused on the role of early childhood and childcare interventions. These discussions focused on early childhood obesity prevention strategies, highlighting recent accomplishments, ongoing problems, and areas where philanthropic support may impact sensible policy change that would give families enhanced child health support and involvement.

Competitive Landscape

Major key players in the bariatric surgery devices market are ReShape Lifesciences, Inc., Covidien Plc, Johnson and Johnson, Cousin Biotech, Mediflex Surgical, Intuitive Surgical Inc., GI Dynamics Inc., TransEnterix Inc., USGI Medical Inc., and Semiled Ltd.

ReShape Lifesciences, Inc.:

Overview:

ReShape Lifesciences is America’s premier weight-loss solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band program provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as gastric bypass or sleeve gastrectomy. The ReShape Vest System is an investigational (outside the U.S.) minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery. It helps enable rapid weight loss in obese and morbidly obese patients without permanently changing patient anatomy. The recently launched ReShapeCare Virtual health coaching program is a virtual telehealth weight management program that supports lifestyle changes for all weight-loss patients to help them keep the weight off over time.

Product Portfolio:

Lap-Band System: The Lap-Band System is indicated for weight reduction for patients with obesity, with a Body Mass Index (BMI) of at least 40 kg/m2 or a BMI of at least 30 kg/m2 with one or more obesity-related comorbid conditions. It is indicated for use only in adult patients who have failed more conservative weight reduction alternatives, such as supervised diet, exercise and behavior modification programs.

The global bariatric surgery devices market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.